Bank of America has revised its price target for Crispr Therapeutics (CRSP, Financial), reducing it to $80 from the previous $86, although it maintains a Buy rating on the company's shares. This adjustment comes as the first quarter earnings season approaches, with a focus expected on commercial launches among small to mid-cap biotech companies under the analyst's coverage.
In addition to these earnings discussions, the analyst has noted that broader industry themes such as pharmaceutical tariffs, potential tax implications, and changes within the FDA could influence investor sentiment across the sector. These elements are anticipated to add a layer of complexity to market perspectives as companies report their financial results.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $81.57 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 115.90% from the current price of $37.78. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $25.46, suggesting a downside of 32.61% from the current price of $37.78. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
